William Blair restated their buy rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a report issued on Friday, AnalystRatings.com reports.

Other research analysts have also recently issued research reports about the stock. Citigroup set a $150.00 price objective on shares of Alexion Pharmaceuticals and gave the company a buy rating in a report on Friday, August 30th. ValuEngine upgraded shares of Alexion Pharmaceuticals from a strong sell rating to a sell rating in a report on Wednesday, October 2nd. Morgan Stanley reduced their price target on shares of Alexion Pharmaceuticals from $177.00 to $170.00 and set an overweight rating on the stock in a research report on Friday, October 11th. Cowen reissued a buy rating and issued a $165.00 price target on shares of Alexion Pharmaceuticals in a report on Wednesday, October 16th. Finally, Raymond James set a $168.00 price objective on shares of Alexion Pharmaceuticals and gave the company a buy rating in a research report on Friday, August 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $156.37.

Shares of Alexion Pharmaceuticals stock traded up $6.47 during trading on Friday, reaching $113.89. 4,286,116 shares of the company were exchanged, compared to its average volume of 1,801,632. The business has a 50-day moving average price of $108.47 and a 200-day moving average price of $112.81. The firm has a market capitalization of $25.20 billion, a price-to-earnings ratio of 16.06, a P/E/G ratio of 1.08 and a beta of 1.67. The company has a quick ratio of 3.45, a current ratio of 3.98 and a debt-to-equity ratio of 0.25. Alexion Pharmaceuticals has a twelve month low of $92.56 and a twelve month high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 EPS for the quarter, beating analysts’ consensus estimates of $2.47 by $0.32. The company had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.24 billion. Alexion Pharmaceuticals had a return on equity of 21.21% and a net margin of 31.05%. Alexion Pharmaceuticals’s revenue was up 23.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.02 EPS. On average, equities research analysts forecast that Alexion Pharmaceuticals will post 9.43 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the company. Signaturefd LLC boosted its position in shares of Alexion Pharmaceuticals by 13.2% during the second quarter. Signaturefd LLC now owns 822 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 96 shares during the period. Investors Research Corp boosted its position in Alexion Pharmaceuticals by 52.0% during the 3rd quarter. Investors Research Corp now owns 304 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 104 shares during the last quarter. Synovus Financial Corp boosted its position in Alexion Pharmaceuticals by 4.6% during the 3rd quarter. Synovus Financial Corp now owns 2,391 shares of the biopharmaceutical company’s stock worth $230,000 after acquiring an additional 106 shares during the last quarter. Fort Washington Investment Advisors Inc. OH grew its stake in shares of Alexion Pharmaceuticals by 6.5% during the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,810 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 111 shares in the last quarter. Finally, Verity Asset Management Inc. grew its stake in shares of Alexion Pharmaceuticals by 4.1% during the 2nd quarter. Verity Asset Management Inc. now owns 2,842 shares of the biopharmaceutical company’s stock worth $372,000 after acquiring an additional 112 shares in the last quarter. 91.60% of the stock is owned by institutional investors.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Further Reading: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.